Monoclonal antibodies against claudin-18 for treatment of cancer
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-016/00
A61K-039/395
C07K-016/18
A61K-047/48
A61K-051/10
C07K-016/30
A61K-045/06
A61K-039/00
출원번호
US-0306545
(2011-11-29)
등록번호
US-9499609
(2016-11-22)
우선권정보
EP-05025657 (2005-11-24)
발명자
/ 주소
Sahin, Ugur
Türeci, Özlem
Usener, Dirk
Fritz, Stefan
Uherek, Christoph
Brandenburg, Gunda
Geppert, Harald-Gerhard
Schröder, Anja Kristina
Thiel, Phillippe
출원인 / 주소
GANYMED PHARMACEUTICALS AG
대리인 / 주소
McAndrews, Held & Malloy, Ltd.
인용정보
피인용 횟수 :
0인용 특허 :
90
초록▼
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD1 8, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer,
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD1 8, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
대표청구항▼
1. An antibody having the ability of binding to CLD18 and mediating killing of cells expressing CLD18, wherein the antibody binds to CLD18A2 but not to CLD18A1 and wherein the antibody binds to an epitope within loopD3 consisting of SEQ ID NO: 29 of CLD18A2, and said killing of cells is mediated by
1. An antibody having the ability of binding to CLD18 and mediating killing of cells expressing CLD18, wherein the antibody binds to CLD18A2 but not to CLD18A1 and wherein the antibody binds to an epitope within loopD3 consisting of SEQ ID NO: 29 of CLD18A2, and said killing of cells is mediated by inducing CDC mediated lysis and/or ADCC mediated lysis. 2. The antibody of claim 1 wherein said killing of cells is induced by binding of said antibody to CLD18A2 expressed by said cells. 3. The antibody of claim 1 wherein said cells expressing CLD18A2 are cancer cells. 4. The antibody of claim 3 wherein the cancer cells are selected from the group consisting of tumorigenic gastric, esophageal, pancreatic and lung cancer cells. 5. The antibody of claim 1 wherein said ADCC mediated lysis takes place in the presence of effector cells selected from the group consisting of monocytes, mononuclear cells, NK cells and PMNs. 6. The antibody of claim 1 which is a monoclonal, chimeric or humanized antibody, or an antigen-binding fragment of an antibody. 7. The antibody of claim 1 selected from the group consisting of an IgG1, an IgG2, preferably IgG2a and IgG2b, an IgG3, an IgG4, and an IgM antibody. 8. The antibody of claim 1 wherein CLD18A2 has the amino acid sequence according to SEQ ID NO:2. 9. The antibody of claim 1 wherein CLD18A1 has the amino acid sequence according to SEQ ID NO:8. 10. The antibody of claim 1 which is specific for cancer cells, preferably stomach cancer cells. 11. The antibody of claim 1 wherein said CLD18A2 is expressed on the surface of said cells. 12. The antibody of claim 1 which is obtainable by a method comprising the step of immunizing an animal with a protein or peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 18, 20, and 31, or an immunogenic fragment thereof, or a nucleic acid or host cell expressing said protein or peptide, or immunogenic fragment thereof. 13. A hybridoma capable of producing the antibody of claim 1. 14. A conjugate comprising an antibody of claim 1 coupled to a therapeutic agent. 15. The conjugate of claim 14 wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent. 16. A pharmaceutical composition comprising an antibody of claim 1, and a pharmaceutically acceptable carrier. 17. An antibody having the ability of binding to CLD18 and mediating killing of cells expressing CLD18, wherein the antibody binds to CLD18A2 but not to CLD18A1 and wherein the antibody binds to the amino acid sequence of SEQ ID NO: 29, and said killing of cells is mediated by inducing CDC mediated lysis and/or ADCC mediated lysis. 18. An antibody having the ability of binding to CLD18 and mediating killing of cells expressing CLD18, wherein the antibody binds to CLD18A2 but not to CLD18A1 and wherein the antibody binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 29, and said killing of cells is mediated by inducing CDC mediated lysis and/or ADCC mediated lysis. 19. A method of killing a cancer cell expressing CLD18A2, comprising contacting the cell with an effective amount of an antibody of claim 1. 20. A method of treating cancer involving cells expressing CLD18A2, comprising administering to a subject an antibody of claim 1. 21. The method of claim 20 wherein the cancer is selected from the group consisting of gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (90)
Presta Leonard G. ; Snedecor Bradley R., Altered polypeptides with increased half-life.
Goddard,Audrey; Godowski,Paul J.; Grimaldi,J. Christopher; Gurney,Austin L.; Wood,William I., Antibodies that recognize a polypeptide overexpressed in rectal tumors.
Goddard,Audrey; Godowski,Paul J.; Grimaldi,J. Christopher; Gurney,Austin L.; Wood,William I., Antibodies to a polypeptide encoded by a nucleic acid differentially expressed in melanoma.
Goddard,Audrey; Godowski,Paul J.; Grimaldi,J. Christopher; Gurney,Austin L.; Wood,William I., Antibodies to a polypeptide encoded by a nucleic acid underexpressed in lung tumor.
Goddard,Audrey; Godowski,Paul J.; Grimaldi,J. Christopher; Gurney,Austin L.; Wood,William I., Antibodies to a polypeptide encoded by a nucleic acid underexpressed in melanoma.
Ladner Robert C. (Iamsville MD), Computer based system and method for determining and displaying possible chemical structures for converting double- or m.
Winter Gregory Paul (Cambridge GB3) Duncan Alexander Robert (Wimbledon GBX) Burton Dennis Raymond (Sheffield GB3), DNA encoding antibodies with altered effector functions.
Türeci, Özlem; Sahin, Ugur; Koslowski, Michael; Fritz, Stefan; Geppert, Harald-Gerhard, Genetic products differentially expressed in tumors and the use thereof.
Ladner Robert C. (Ijamsville MD) Bird Robert E. (Rockville MD) Hardman Karl (Chevy Chase MD), Immunotheraphy using single chain polypeptide binding molecules.
La Zor Clair G. (13054 Rose St. Cerritos CA 90701), Instrument for locating faults in aircraft passenger reading light and attendant call control system.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Loughrey Helen C. (Vancouver CAX) Cullis Pieter R. (Vancouver CAX) Bally Marcel B. (Bowen Island CAX) Choi Lewis S. (Burnaby CAX), Method for protein-liposome coupling.
Fanger Michael W. (Lebanon NH) Guyre Paul M. (Hanover NH) Anderson Clark L. (Columbus OH), Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Goddard,Audrey; Godowski,Paul J.; Grimaldi,J. Christopher; Gurney,Austin L.; Wood,William I., Polypeptides encoded by a nucleic acid are expressed in esophageal and kidney tumor.
Huston James S. (Newton MA) Charette Marc F. (West Roxbury MA) Cohen Charles M. (Medway MA) Crea Roberto (Boston MA) Keck Peter C. (Millbury MA) Oppermann Hermann (Medway MA) Rueger David C. (West Ro, Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage.
Eaton,Dan L.; Goddard,Audrey; Godowski,Paul J.; Gurney,Austin L.; Wood,William I., Secreted and transmembrane polypeptides and nucleic acids encoding the same.
Eaton,Dan L.; Goddard,Audrey; Godowski,Paul J.; Gurney,Austin L.; Wood,William I., Secreted and transmembrane polypeptides and nucleic acids encoding the same.
Ferrara, Napoleone; Goddard, Audrey; Godowski, Paul J.; Gurney, Austin L.; Pan, James; Watanabe, Colin K.; Wood, William I., Secreted and transmembrane polypeptides and nucleic acids encoding the same.
Goddard,Audrey; Godowski,Paul J.; Grimaldi,J. Christopher; Gurney,Austin L.; Wood,William I., Secreted and transmembrane polypeptides and nucleic acids encoding the same.
Goddard,Audrey; Godowski,Paul J.; Grimaldi,J. Christopher; Gurney,Austin L.; Wood,William I., Secreted and transmembrane polypeptides and nucleic acids encoding the same.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.